About FBMFarmaFBMPharma, founded in 2000, has become a leading pharmaceutical manufacturer and distributor in Brazil, the seventh largest and second fastest growing economy in the world. Employing over 1,000 people FBMFarma distributes a wide range of medical products, including pharmaceuticals, blood derivatives, medical devices and intraocular lens. FBMFarma's six state-of-the-art manufacturing facilities produce an array of medicines, cosmetics, medical devices and nutritional products. FBMFarma has eight regional sales and distribution facilities strategically deployed to serve all parts of Brazil with the goal of providing same day delivery of its products. Its success is the result of a constant concern for excellence in service with quality, responsibility and ethics. About Ampio Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com. Forward-Looking Statements Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.